You are in: eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease Animal BitesArticle Last Updated: Jul 14, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Clifford S Spanierman, MD, Consulting Staff, Departments of Emergency Medicine and Pediatrics, Lutheran General Hospital of Oak Brook, Advocate Health System Editors: Harold K Simon, MD, MBA, Professor of Pediatrics and Emergency Medicine, Associate Division Director of Pediatric Emergency Medicine, Director of Research, Division of Pediatric Emergency Medicine, Emory University School of Medicine, Children's Healthcare of Atlanta at Egleston; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Wayne Wolfram, MD, MPH, Clinical Associate Professor, Departments of Pediatrics, Children's Hospital and University of Cincinnati; Paul D Petry, DO, FACOP, FAAP, Consulting Staff, Freeman Pediatric Care, Freeman Health System; Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine Author and Editor Disclosure Synonyms and related keywords: animal bites, dog bites, cat bites, bite-related infection, mammal bites, rodent bites, ferret bites, rabbit bites, pit bull bite, pet bites, bite wound infection, cellulitis, rabies, septic arthritis, animal bites, Staphylococcus, Streptococcus, Pasteurella, Bacteroides, Capnocytophaga canimorsus, Eikenella, Enterobacter, Proteus, Haemophilus, Klebsiella, Actinomyces, Fusobacterium, Peptostreptococcus, Clostridium, Wolinella, Propionibacterium, osteomyelitis INTRODUCTIONBackgroundEstimates indicate that more than 5 million Americans are bitten by animals each year. Dogs and cats are involved in most of these bites. Bites from both cats and dogs require careful management, and patients may experience long-term morbidity or may even die. Cat bites have a high incidence of infection (approximately 50%), and dog bites may cause severe injury to tissues. Dog and cat populations in the United States are each estimated to exceed 50 million animals. Many households in the United States include pets, and many children are bitten by family pets. Breeds associated with serious dog bites in children include pit bull, Rottweiler, wolf mix, Saint Bernard, German Shepherd, and Akita. PathophysiologyDogs and cats have prominent canine teeth; however, great differences are observed in the structure of those teeth. Dogs have wider canines, while cats have thinner canines. Dogs are capable of exerting enormous pressure when biting, and some breeds can pierce metal plates with their teeth. In particular, the bites of large dogs can be dangerous to children. Large breeds tend to cause wounds in the head and neck areas of younger children, and their powerful jaws can penetrate the skull and destroy deep tissue. Cat bites are characterized by puncture wounds that inoculate bacteria deep into tissues. Cats and dogs harbor a number of potentially pathogenic species of aerobic and anaerobic bacteria in the oral flora.1 Common genera include Staphylococcus, Streptococcus, Pasteurella, and Bacteroides.2 Other organisms cultured in dog bites include Capnocytophaga canimorsus and species of Eikenella, Enterobacter, Proteus, Haemophilus, and Klebsiella. Cat bites may contain Actinomyces, Fusobacterium, Peptostreptococcus, Clostridium, Wolinella, and Propionibacterium organisms. Infections should be assumed to be polymicrobial. FrequencyUnited StatesEstimates indicate that more than 5 million Americans are bitten by animals each year. Dog bites account for nearly 85% of the total number of animal bites, and cat bites for approximately 10%. Other animals involved in bites include rodents and other small mammals, such as ferrets and rabbits. Bites from more exotic animals (eg, snakes, lizards, monkeys, farm animals) are rare. InternationalTypes of animal bites can vary depending on land development and the natural flora. For example, in India, tiger bites may be encountered. In general, in North America, dogs are the agents in most animal bites. Mortality/MorbidityEach year, approximately 20 people die as a result of dog bites; most of these people are young children who have massive neck and head injuries resulting from the bites. The mouths in breeds of large dogs are at the height of young children's faces. Pit bulls, with powerful jaws that are capable of causing rapid and devastating damage, are responsible for nearly three fourths of all dog bite fatalities.
SexMales are more likely than females to be bitten by dogs.3 Females are more likely than males to be bitten by cats. AgeAnimal bites are most common in children aged 5-14 years. CLINICALHistoryBegin taking the history with prehospital care.
Physical
CausesBites may be either provoked or unprovoked.
DIFFERENTIALSArthritis, Septic Human Bites Osteomyelitis Rabies Tetanus
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Amoxicillin clavulanate (Augmentin) |
|---|---|
| Description | Combination antibiotic containing amoxicillin with a beta-lactamase inhibitor, which extends the antibiotic spectrum. Overall, the spectrum of this antibiotic provides the best prophylaxis against potential pathogens. Dose is based on the amoxicillin content. |
| Adult Dose | 500 mg PO tid or 875 mg PO bid |
| Pediatric Dose | <3 months: 30-40 mg/kg/d PO divided bid (use 125 mg/5 mL susp) >3 months: 45 mg/kg/d PO divided q12h (use 200 or 400 mg/5 mL susp) If 125 or 250 mg/5mL susp is used, administer 40 mg/kg/d PO divided q8h |
| Contraindications | Documented hypersensitivity; prior Augmentin-induced hepatic dysfunction |
| Interactions | Coadministration with warfarin or heparin increases risk of bleeding; probenecid may inhibit renal tubular secretion of amoxicillin, thus increasing levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver dysfunction and pseudomembranous colitis; administer with food; common adverse reactions include rash and gastrointestinal tract upset |
| Drug Name | Ampicillin-sulbactam (Unasyn) |
|---|---|
| Description | Treatment of choice for infected bites with a spectrum similar to Augmentin. Contains two-thirds ampicillin and one-third sulbactam. Pediatric doses are based on ampicillin component. |
| Adult Dose | 1.5 g (1 g ampicillin plus 0.5 g sulbactam) IV q6h |
| Pediatric Dose | 100-150 ampicillin/kg/d IV divided q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid and disulfiram elevate ampicillin levels; allopurinol decreases ampicillin effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Pseudomembranous colitis; evaluate rash and differentiate from hypersensitivity reaction; adjust dose in renal failure |
| Drug Name | Trimethoprim and sulfamethoxazole (Bactrim, Septra) |
|---|---|
| Description | Used in combination with clindamycin for prophylaxis or treatment in patients allergic to penicillin. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid. Trimethoprim blocks the production of tetrahydrofolic acid by inhibiting the enzyme dihydrofolate reductase. Two consecutive steps in bacterial biosynthesis of essential nucleic acids and proteins are blocked with this combination. In vitro bacterial resistance is slower to develop with this combination than with either drug alone. |
| Adult Dose | 160 mg trimethoprim/800 mg sulfamethoxazole PO q12h (ie, 1 double-strength tab q12h) |
| Pediatric Dose | <2 months: Do not administer >2 months: 8-10 mg/kg/d (based on trimethoprim component) PO divided q12h |
| Contraindications | Documented hypersensitivity; anemia caused by folate deficiency |
| Interactions | May increase PT when used with warfarin (perform coagulation tests and adjust dose accordingly); coadministration with dapsone may increase blood levels of both drugs; coadministration with diuretics increases incidence of thrombocytopenia purpura in elderly patients; phenytoin levels may increase with coadministration; may potentiate effects of methotrexate in bone marrow depression; hypoglycemic response to sulfonylureas may increase with coadministration; may increase levels of zidovudine |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use in pregnancy near term (risk of kernicterus); may cause Stevens-Johnson syndrome and toxic epidermal necrolysis; discontinue at first appearance of rash or signs of adverse reaction (eg, rash, sore throat, fever, arthralgia, cough, shortness of breath, pallor, purpura, jaundice); hepatic necrosis; aplastic anemia; agranulocytosis; hemolysis may occur in patients with G-6-PD deficiency (dose related); caution in renal or hepatic impairment |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Used for prophylaxis and treatment of animal bites in combination with trimethoprim/sulfamethoxazole; inhibits bacterial protein synthesis by its action at the bacterial ribosome; binds to 50S ribosomal subunit and affects process of peptide chain initiation. |
| Adult Dose | 150-450 mg PO q6-8h 1200-1800 mg IV divided tid/qid |
| Pediatric Dose | 10-30 mg/kg/d PO divided tid/qid 25-40 mg/kg/d IV divided q6-8h |
| Contraindications | Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis |
| Interactions | Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Pseudomembranous colitis; adjust dose in severe hepatic dysfunction; no adjustment necessary in renal failure; advise patients to take cap with full glass of water |
| Drug Name | Erythromycin (EES, E-Mycin, Ery-Tab, Erythrocin) |
|---|---|
| Description | For prophylactic use in patients allergic to penicillin; macrolide antibiotic with a large spectrum of activity; binds to 50S ribosomal subunit to inhibit protein synthesis. |
| Adult Dose | 250-500 mg PO qid or 400-800 mg (ethylsuccinate) PO tid |
| Pediatric Dose | 30-50 mg/kg/d PO divided q6-8h |
| Contraindications | Documented hypersensitivity; hepatic impairment; concomitant administration of terfenadine (recalled from US market), cisapride, or astemizole (recalled from US market) |
| Interactions | Decreases clearance of terfenadine (recalled from US market), cisapride, and astemizole (recalled from US market), which may result in serious cardiac arrhythmias; decreases clearance of cyclosporine, midazolam, phenytoin, triazolam, theophylline, and carbamazepine; may increase warfarin toxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Impaired hepatic function, abdominal pain, diarrhea, nausea, and vomiting |
| Drug Name | Ceftriaxone (Rocephin) |
|---|---|
| Description | Third-generation cephalosporin with broad-spectrum gram-negative activity; lower efficacy against gram-positive organisms; higher efficacy against resistant organisms. Arrests bacterial growth by binding to one or more penicillin-binding proteins. |
| Adult Dose | Uncomplicated infections: 250 mg IM once; not to exceed 4 g Severe infections: 1-2 g IV qd or divided bid; not to exceed 4 g/d |
| Pediatric Dose | Neonates >7 days: 25-50 mg/kg/d IV/IM; not to exceed 125 mg/d Infants and children: 50-75 mg/kg/d IV/IM divided q12h; not to exceed 2 g/d |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase ceftriaxone levels; coadministration with ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in severe renal insufficiency (high doses may cause CNS toxicity); superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy; caution in breastfeeding |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and, possibly, 50S ribosomal subunits. |
| Adult Dose | 250-500 mg PO q6h Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d Severe infections: 500 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 25-50 mg/kg/d PO divided qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of PO contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
These agents provide active and passive immunization and increase resistance to infection.
| Drug Name | Tetanus toxoid |
|---|---|
| Description | The immunizing agent of choice for most adults and children >7 y is tetanus and diphtheria toxoids (Td). Necessary to administer booster doses to maintain tetanus immunity throughout life. Patients who are pregnant should receive only tetanus toxoid, not a diphtheria antigen-containing product. In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is the mid thigh laterally. |
| Adult Dose | Primary immunization: 0.5 mL IM, give 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection Booster dose: 0.5 mL q10y |
| Pediatric Dose | <7 years: Assure primary immunization with DTP and DTaP has been completed, if incomplete, administer vaccine series according to CDC guidelines >7 years: Administer as in adults; Tdap is the preferred vaccine for adolescents (10-18 y) |
| Contraindications | Documented hypersensitivity; history of any type of neurologic symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol because it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude its concurrent use) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use to treat actual tetanus infections, or for immediate prophylaxis of unimmunized individuals (instead use tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended |
| Drug Name | Rabies vaccine (Imovax, RabAvert) |
|---|---|
| Description | Inactivated form of virus grown in primary cultures of chicken fibroblasts; offers active immunity and, when used in combination with human rabies immune globulin (HRIG) and local wound treatment, protects postexposure patients of all age groups; also used for preexposure immunization in both primary series and booster dose. Fourteen days after initiating immunization series, antirabies antibody titers reach levels well above minimal protective level of 0.5 IU/mL. |
| Adult Dose | Preexposure immunization: 1 mL IM days 0, 3, 7, 14, and 28, and then q2-5y depending on antibody titers Postexposure prophylaxis (previously unvaccinated patients): Administer RIG (20 IU/kg) as soon as possible after exposure, and a total of 5 IM doses each 1 mL on days 0, 3, 7, 14, and 28 Previously immunized patients (documented titers): IM doses days 0 and 3 (one dose each day); do not administer RIG |
| Pediatric Dose | Administer as in adults |
| Contraindications | None reported for postexposure immunization (if alternative products are not available, caution in persons known to be sensitive to neomycin, amphotericin B, chlortetracycline, processed bovine gelatin, and chicken protein because trace amounts of these products may be present in the vaccine) |
| Interactions | Corticosteroids, antimalarials, and other immunosuppressive agents may reduce protective efficacy of vaccine; persons receiving immunosuppressive therapy should receive RIG (3 doses/mL each) IM |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in documented hypersensitivity (may pretreat such patients with antihistamines); never inject rabies vaccine in gluteal area; epinephrine injection (1:1000), volume replacement, oxygen, and corticosteroids must be immediately available to counteract anaphylactic reactions that may occur |
| Drug Name | Rabies immune globulin (BayRab, Imogam) |
|---|---|
| Description | Provides passive protection to individuals exposed to rabies virus. About one half the dose should be administered into and around the bite wound as much as possible (given anatomic constraints), and the rest given IM at a site remote from the vaccine administration area, in the gluteal or deltoid muscle. |
| Adult Dose | 20 IU/kg; most or all of solution is infiltrated around the wound; any remaining solution should be administered IM in the gluteus once after exposure, preferably with first dose of vaccine; not to exceed 20 IU/kg |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; to prevent interference with a maximum active immunity from rabies vaccine, do not administer in repeated doses once the rabies vaccine treatment has been initiated |
| Interactions | Through an antigen-antibody antagonism, RIG may diminish antibody response to MMR vaccine; should administer live virus vaccines 14-30 d before or 6-12 wk after immune globulin administration; antibody response to rabies vaccine may be delayed if administered simultaneously with rabies immunoglobulins |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in thrombocytopenia or bleeding disorders |
| Media file 1: The devastating damage sustained by a preadolescent male during a pit bull attack. Almost lost in this photograph is the soft tissue damage to this victim's thigh. This patient required 2 units of O- blood and several liters of isotonic crystalloid. Repair of these wounds required a pediatric surgeon, an experienced orthopedic surgeon, and a plastic surgeon. Attacks such as these have caused a movement in some areas of the country to ban pit bulls. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Massive soft tissue damage of the right leg caused by a pit bull attack. This patient was transferred to a level one pediatric trauma center for care. At times, staff members may need counseling after caring for savagely mauled patients. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Massive soft tissue damage of the lower left leg caused by a pit bull attack. Most of the fatalities from dog bites are children. Rottweilers and pit bulls are responsible for about 60% of fatalities. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 4: A different angle of the patient in Image 3 showing the massive soft tissue damage to this child's left lower leg. Pit bull attacks are not rare. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 5: Wounds to the left arm inflicted during a pit bull attack. This young patient was also bitten once on the left side of his face. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Jul 14, 2008